Logo image of BDSX

BIODESIX INC (BDSX) Stock Fundamental Analysis

NASDAQ:BDSX - US09075X1081 - Common Stock

0.4895 USD
+0.04 (+7.96%)
Last: 8/25/2025, 8:06:03 PM
0.473 USD
-0.02 (-3.37%)
After Hours: 8/25/2025, 8:06:03 PM
Fundamental Rating

3

Taking everything into account, BDSX scores 3 out of 10 in our fundamental rating. BDSX was compared to 101 industry peers in the Health Care Providers & Services industry. BDSX may be in some trouble as it scores bad on both profitability and health. BDSX is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year BDSX has reported negative net income.
BDSX had a negative operating cash flow in the past year.
In the past 5 years BDSX always reported negative net income.
BDSX had a negative operating cash flow in each of the past 5 years.
BDSX Yearly Net Income VS EBIT VS OCF VS FCFBDSX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

The Return On Assets of BDSX (-46.82%) is worse than 91.09% of its industry peers.
With a Return On Equity value of -3609.67%, BDSX is not doing good in the industry: 84.16% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -46.82%
ROE -3609.67%
ROIC N/A
ROA(3y)-55.74%
ROA(5y)-49.96%
ROE(3y)-553.97%
ROE(5y)-391.42%
ROIC(3y)N/A
ROIC(5y)N/A
BDSX Yearly ROA, ROE, ROICBDSX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

1.3 Margins

BDSX's Gross Margin of 78.77% is amongst the best of the industry. BDSX outperforms 93.07% of its industry peers.
BDSX's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for BDSX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 78.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.1%
GM growth 5Y0.76%
BDSX Yearly Profit, Operating, Gross MarginsBDSX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

3

2. Health

2.1 Basic Checks

BDSX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, BDSX has more shares outstanding
BDSX has more shares outstanding than it did 5 years ago.
BDSX has a worse debt/assets ratio than last year.
BDSX Yearly Shares OutstandingBDSX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M
BDSX Yearly Total Debt VS Total AssetsBDSX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -7.45, we must say that BDSX is in the distress zone and has some risk of bankruptcy.
BDSX has a Altman-Z score of -7.45. This is amonst the worse of the industry: BDSX underperforms 91.09% of its industry peers.
A Debt/Equity ratio of 41.11 is on the high side and indicates that BDSX has dependencies on debt financing.
BDSX has a Debt to Equity ratio of 41.11. This is amonst the worse of the industry: BDSX underperforms 84.16% of its industry peers.
Industry RankSector Rank
Debt/Equity 41.11
Debt/FCF N/A
Altman-Z -7.45
ROIC/WACCN/A
WACC11.9%
BDSX Yearly LT Debt VS Equity VS FCFBDSX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

2.3 Liquidity

A Current Ratio of 2.14 indicates that BDSX has no problem at all paying its short term obligations.
BDSX's Current ratio of 2.14 is fine compared to the rest of the industry. BDSX outperforms 77.23% of its industry peers.
BDSX has a Quick Ratio of 2.14. This indicates that BDSX is financially healthy and has no problem in meeting its short term obligations.
BDSX has a Quick ratio of 2.14. This is in the better half of the industry: BDSX outperforms 78.22% of its industry peers.
Industry RankSector Rank
Current Ratio 2.14
Quick Ratio 2.14
BDSX Yearly Current Assets VS Current LiabilitesBDSX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 36.96% over the past year.
Looking at the last year, BDSX shows a very strong growth in Revenue. The Revenue has grown by 25.71%.
BDSX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 23.78% yearly.
EPS 1Y (TTM)36.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)25.71%
Revenue growth 3Y9.37%
Revenue growth 5Y23.78%
Sales Q2Q%11.68%

3.2 Future

Based on estimates for the next years, BDSX will show a quite strong growth in Earnings Per Share. The EPS will grow by 19.55% on average per year.
Based on estimates for the next years, BDSX will show a very strong growth in Revenue. The Revenue will grow by 20.16% on average per year.
EPS Next Y17.67%
EPS Next 2Y21.17%
EPS Next 3Y19.55%
EPS Next 5YN/A
Revenue Next Year17.45%
Revenue Next 2Y22.49%
Revenue Next 3Y20.16%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
BDSX Yearly Revenue VS EstimatesBDSX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
BDSX Yearly EPS VS EstimatesBDSX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BDSX. In the last year negative earnings were reported.
Also next year BDSX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BDSX Price Earnings VS Forward Price EarningsBDSX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BDSX Per share dataBDSX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

BDSX's earnings are expected to grow with 19.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.17%
EPS Next 3Y19.55%

More info and screens

0

5. Dividend

5.1 Amount

BDSX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIODESIX INC

NASDAQ:BDSX (8/25/2025, 8:06:03 PM)

After market: 0.473 -0.02 (-3.37%)

0.4895

+0.04 (+7.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)10-30 2025-10-30/amc
Inst Owners33.44%
Inst Owner Change-32.96%
Ins Owners25.97%
Ins Owner Change3.65%
Market Cap71.78M
Analysts80
Price Target1.79 (265.68%)
Short Float %6.07%
Short Ratio2.7
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-15.06%
Min EPS beat(2)-15.34%
Max EPS beat(2)-14.78%
EPS beat(4)2
Avg EPS beat(4)-2.99%
Min EPS beat(4)-15.34%
Max EPS beat(4)11.77%
EPS beat(8)6
Avg EPS beat(8)3.3%
EPS beat(12)8
Avg EPS beat(12)1.74%
EPS beat(16)11
Avg EPS beat(16)2.05%
Revenue beat(2)1
Avg Revenue beat(2)-1.63%
Min Revenue beat(2)-9.55%
Max Revenue beat(2)6.29%
Revenue beat(4)2
Avg Revenue beat(4)-1.73%
Min Revenue beat(4)-9.55%
Max Revenue beat(4)6.29%
Revenue beat(8)4
Avg Revenue beat(8)-1.48%
Revenue beat(12)6
Avg Revenue beat(12)-1.3%
Revenue beat(16)8
Avg Revenue beat(16)0.19%
PT rev (1m)-2.78%
PT rev (3m)-44%
EPS NQ rev (1m)-29.17%
EPS NQ rev (3m)-43.52%
EPS NY rev (1m)-16.1%
EPS NY rev (3m)-16.89%
Revenue NQ rev (1m)0.02%
Revenue NQ rev (3m)-11.89%
Revenue NY rev (1m)1.29%
Revenue NY rev (3m)-0.94%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.94
P/FCF N/A
P/OCF N/A
P/B 63.07
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.29
EYN/A
EPS(NY)-0.19
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.2
OCFYN/A
SpS0.52
BVpS0.01
TBVpS-0.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -46.82%
ROE -3609.67%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 78.77%
FCFM N/A
ROA(3y)-55.74%
ROA(5y)-49.96%
ROE(3y)-553.97%
ROE(5y)-391.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.1%
GM growth 5Y0.76%
F-Score3
Asset Turnover0.87
Health
Industry RankSector Rank
Debt/Equity 41.11
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 24.1%
Cap/Sales 1.83%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.14
Quick Ratio 2.14
Altman-Z -7.45
F-Score3
WACC11.9%
ROIC/WACCN/A
Cap/Depr(3y)283.54%
Cap/Depr(5y)201.2%
Cap/Sales(3y)20.35%
Cap/Sales(5y)14.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.96%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y17.67%
EPS Next 2Y21.17%
EPS Next 3Y19.55%
EPS Next 5YN/A
Revenue 1Y (TTM)25.71%
Revenue growth 3Y9.37%
Revenue growth 5Y23.78%
Sales Q2Q%11.68%
Revenue Next Year17.45%
Revenue Next 2Y22.49%
Revenue Next 3Y20.16%
Revenue Next 5YN/A
EBIT growth 1Y-2.28%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year53.86%
EBIT Next 3Y31.94%
EBIT Next 5YN/A
FCF growth 1Y31.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.12%
OCF growth 3YN/A
OCF growth 5YN/A